Low dose 2-CdA schedule activity in splenic marginal zone lymphomas

2003 ◽  
Vol 21 (4) ◽  
pp. 163-168 ◽  
Author(s):  
R. Riccioni ◽  
F. Caracciolo ◽  
S. Galimberti ◽  
N. Cecconi ◽  
M. Petrini
Keyword(s):  
Low Dose ◽  
Marginal Zone ◽  
Schedule Activity

scholarly journals Antimorphic goosecoids

Development ◽  
1998 ◽  
Vol 125 (8) ◽  
pp. 1347-1359 ◽  
Author(s):  
B. Ferreiro ◽  
M. Artinger ◽  
K. Cho ◽  
C. Niehrs
Keyword(s):  
Transcriptional Activation ◽  
Low Dose ◽  
Marginal Zone ◽  
Homeobox Gene ◽  
Axis Formation ◽  
Wild Type ◽  
Transcriptional Activation Domain ◽  
Spemann Organizer ◽  
Axial Defects ◽  
Dorsal Mesoderm

goosecoid (gsc) is a homeobox gene expressed in the Spemann organizer that has been implicated in vertebrate axis formation. Here antimorphic gscs are described. One antimorphic gsc (MTgsc) was fortuitously created by adding 5 myc epitopes to the N terminus of gsc. The other antimorph (VP16gsc) contains the transcriptional activation domain of VP16. mRNA injection of either antimorph inhibits dorsal gastrulation movements and leads to embryos with severe axial defects. They upregulate ventral gene expression in the dorsal marginal zone and inhibit dorsal mesoderm differentiation. Like the VP16 domain, the N-terminal myc tags act by converting wild-type gsc from a transcriptional repressor into an activator. However, unlike MTgsc, VP16gsc is able at low dose to uncouple head from trunk formation, indicating that different antimorphs may elicit distinct phenotypes. The experiments reveal that gsc and/or gsc-related genes function in axis formation and gastrulation. Moreover, this work warns against using myc tags indiscriminately for labeling DNA-binding proteins.

PO-0920: Low dose radiation therapy (2 Gy x 2) in the treatment of Marginal Zone Lymphomas

2020 ◽  
Vol 152 ◽  
pp. S491-S492
Author(s):  
V. De Luca ◽  
S. Bartoncini ◽  
G.C. Iorio ◽  
R. Parise ◽  
E. Orlandi ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Low Dose ◽  
Marginal Zone ◽  
Low Dose Radiation ◽  
Dose Radiation

scholarly journals Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma

2018 ◽  
Vol 50 (2) ◽  
pp. 575-581 ◽  
Author(s):  
Ga-In Lee ◽  
Dongryul Oh ◽  
Won Seog Kim ◽  
Seok Jin Kim ◽  
Young Hyeh Ko ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
B Cell ◽  
Low Dose ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Dose Radiation ◽  
Dose Radiation

An Applicational Observation of Low-Dose Rituximab in Elderly Patients with Nodal Marginal Zone Lymphomas.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4771-4771
Author(s):  
Enrico Roggero ◽  
Antonella Palumbo ◽  
Stefania Di Martino ◽  
Giancarla Busi ◽  
Augusto Pedrazzini
Keyword(s):  
Adverse Events ◽  
Elderly Patients ◽  
Low Dose ◽  
Marginal Zone ◽  
Performance Status ◽  
Single Agent ◽  
Stage Iv ◽  
Biologic Agent ◽  
Median Response ◽  
The Impact

Abstract Background: Single-agent rituximab was shown to prolong overall response rate (ORR) in marginal zone lymphomas. However, despite the confirmed activity of this immuno-biologic agent a significant number of adverse events were reported in this commonly considered indolent lymphoma entity. Methods: To reduce the impact of rituximab toxicity we investigated the activity of low-dose rituximab infusions in 3 consecutive elderly patients (over 70 years) with nodal marginal zone lymphomas. All patients (Ann Arbor stage IV with bone marrow (BM) involvement, age range from 71 to 84 years, normal LDH and WHO performance status = 0) were treated with weekly low-dose rituximab (75 mg/m2) administred for 6 consecutive weeks. Results: All patients complleted the treatment program. No complete response were observed. All patients confirmed a partial response (PR) with reduction of symptoms and disease related BM involvement. The median response duration was 14 months. At a median follow-up of 18 months, 2 patients relapsed and one patient (chemiotherapy naive) is still responding. The 3 patients did not experienced any adverse events and depsite the older age of patients, no expected infusion-related side effects were recorded. Conclusion: This investigative report demostrated the efficacy and the well tolerability of low-dose rituximab (75 mg/m2 administreted weekly for 6 consecutive weeks) in elderly patients with well defined diagnosis of nodal marginal zone lymphoma. These observations can lead to the hypothesis that the dose and the schedule of rituximab should be redefined in this lymphoma entity.

Ocular adnexal marginal zone B-cell lymphoma: the low-dose dilemma

2019 ◽  
Vol 104 (2) ◽  
pp. 151-152
Author(s):  
Vincent Camus ◽  
Fabrice Jardin ◽  
Hervé Tilly
Keyword(s):  
B Cell ◽  
Low Dose ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma

Efficacy of low dose radiotherapy for primary orbital marginal zone lymphoma

2012 ◽  
Vol 54 (3) ◽  
pp. 491-496 ◽  
Author(s):  
Krystel H. Tran ◽  
Belinda A. Campbell ◽  
Tsien Fua ◽  
Michael MacManus ◽  
Gail Ryan ◽  
...  
Keyword(s):  
Low Dose ◽  
Marginal Zone ◽  
Marginal Zone Lymphoma ◽  
Low Dose Radiotherapy

Intra-lesional low-dose interferon α2a therapy for primary cutaneous marginal zone B-cell lymphoma

2006 ◽  
Vol 47 (5) ◽  
pp. 865-869 ◽  
Author(s):  
Antonio Cozzio ◽  
Werner Kempf ◽  
Regula Schmid-Meyer ◽  
Michel Gilliet ◽  
Sonja Michaelis ◽  
...  
Keyword(s):  
B Cell ◽  
Low Dose ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Interferon Α2a
Sign in / Sign up

Export Citation Format

Share Document